piracetam has been researched along with Kidney Failure, Chronic in 6 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Noncompartmental pharmacokinetic parameters were calculated and steady-state profiles were simulated using the superposition method." | 2.79 | Levetiracetam pharmacokinetics in Japanese subjects with renal impairment. ( Kumagai, Y; Stockis, A; Toublanc, N; Yamamoto, J, 2014) |
| " Heparin dosage was not reduced during HD using QB 200 ml, QD 500 ml, and no ultrafiltration." | 2.66 | A pilot study of piracetam in cuprophan hemodialysis. ( Alivanis, P; Grekas, D; Karamouzis, M; Pyrpasopoulos, M; Tourkantonis, A, 1989) |
| " The results of these studies indicate that higher doses need to be used for children (on a per-weight basis), and individuals with renal dysfunction require dosage modifications related to creatinine clearance." | 2.41 | Use of levetiracetam in special populations. ( French, J, 2001) |
| " In end-stage renal disease (ESRD) patients on hemodialysis (HD), pharmacokinetic studies recommend daily dosing with 50% supplemental doses after 4-hour HD sessions." | 1.46 | Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis. ( Sands, KA; Shiue, HJ; Taylor, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shiue, HJ | 1 |
| Taylor, M | 1 |
| Sands, KA | 1 |
| Yamamoto, J | 1 |
| Toublanc, N | 1 |
| Kumagai, Y | 1 |
| Stockis, A | 1 |
| French, J | 1 |
| Schaefer, RM | 1 |
| Seufert, H | 1 |
| Schafferhans, K | 1 |
| Gilge, U | 1 |
| Schulz, HU | 1 |
| Pooth, R | 1 |
| Heidland, A | 1 |
| Grekas, D | 2 |
| Alivanis, P | 2 |
| Karamouzis, M | 2 |
| Pyrpasopoulos, M | 2 |
| Tourkantonis, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for piracetam and Kidney Failure, Chronic
| Article | Year |
|---|---|
Use of levetiracetam in special populations.
Topics: Adult; Age Factors; Aged; Anticonvulsants; Child; Comorbidity; Contraceptives, Oral; Drug Approval; | 2001 |
2 trials available for piracetam and Kidney Failure, Chronic
| Article | Year |
|---|---|
Levetiracetam pharmacokinetics in Japanese subjects with renal impairment.
Topics: Adult; Aged; Animals; Case-Control Studies; Dose-Response Relationship, Drug; Humans; Japan; Kidney | 2014 |
A pilot study of piracetam in cuprophan hemodialysis.
Topics: Adult; Aged; Biocompatible Materials; Cellulose; Female; Humans; Kidney Failure, Chronic; Male; Memb | 1989 |
3 other studies available for piracetam and Kidney Failure, Chronic
| Article | Year |
|---|---|
Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis.
Topics: Adult; Aged; Anticonvulsants; Clinical Protocols; Drug Administration Schedule; Female; Humans; Kidn | 2017 |
[Determination of glomerular filtration rate in man using single shot piracetam clearance].
Topics: Creatinine; Glomerular Filtration Rate; Humans; Infusions, Intravenous; Inulin; Kidney Failure, Chro | 1992 |
Piracetam as a potent inhibitor of plasma thromboxane B2 during hemodialysis.
Topics: Adult; Aged; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piracetam; Pyrrolidinones; | 1989 |